Retinal nerve fiber layer thickness changes in patients with age-related macular degeneration treated with intravitreal ranibizumab

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 10, 2012, Pages 6214-6218

  Martinez de la Casa, Jose M ^a   Ruiz Calvo, Aurora ^a   Saenz Frances, Federico ^a   Reche Frutos, Juan ^a   Calvo Gonzalez, Cristina ^a   Donate Lopez, Juan ^a   Garcia Feijoo, Julián ^a  

^a SCHOOL OF MEDICINE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; LONGITUDINAL STUDY; MACULAR THICKNESS; MALE; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUPIL; RETINA FOVEA; RETINA MACULA AGE RELATED DEGENERATION; RETINAL NERVE FIBER LAYER THICKNESS; SCORING SYSTEM; DRUG EFFECT; FOURIER ANALYSIS; INTRAVITREAL DRUG ADMINISTRATION; METHODOLOGY; MIDDLE AGED; NERVE FIBER; PATHOLOGY; PATHOPHYSIOLOGY; RETINA; RETINA MACULA DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COHORT STUDIES; FEMALE; FOURIER ANALYSIS; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; NERVE FIBERS; PROSPECTIVE STUDIES; RETINA; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 84871703072     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-9875     Document Type: Article

References (18)

1. Rudnicka AR, Mt-Isa S, Owen CG, et al. Variations in primary open-angle glaucoma prevalence by age, gender, and race: a Bayesian meta-analysis. Invest Ophthalmol Vis Sci. 2006;47: 4254-4261.
2. Klaver CC, Wolfs RC, Vingerling JR, et al. Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. Arch Ophthalmol. 1998;116:653-658.
3. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-713.
4. Chang TS, Bressler NM, Fine JT, et al; MARINA Study Group. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol. 2007;125:1460-1469.
5. Bressler NM, Chang TS, Fine JT, et al; Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration (ANCHOR) Research Group. Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Arch Ophthalmol. 2009;127:13-21.
6. Bashshur ZF, Haddad ZA, Schakal A, et al. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol. 2008;145:249-256.
7. Wu L, Martínez-Castellanos MA, Quiroz-Mercado H et al; Pan American Collaborative Retina Group (PACORES). Twelvemonth safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol. 2008;246:81-87.
8. Kim JE, Mantravadi AV, Hur EY, Covert DJ. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol. 2008;146:930-934.
9. Hollands H, Wong J, Bruen R, et al. Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol. 2007;42:807-811.
10. Lanzl IM, Maier M, Feucht N, et al. Intraocular pressure effects of pegaptanib (Macugen) injections in patients with and without glaucoma. Am J Ophthalmol. 2007;143:1034-1035.
11. Zayit-Soudry S, Zemel E, Loewenstein A, Perlman I. Safety evaluation of repeated intravitreal injections of bevacizumab and ranibizumab in rabbit eyes. Retina. 2010;30:671-681.
12. Horsley MB, Mandava N, Maycotte MA, Kahook MY. Retinal nerve fiber layer thickness in patients receiving chronic antivascular endothelial growth factor therapy. Am J Ophthalmol. 2010;150:558-561.
13. Falkenstein IA, Cheng L, Freeman WR. Changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin). Retina. 2007;27:1044-1047.
14. Frenkel MP, Haji SA, Frenkel RE. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections. Arch Ophthalmol. 2010;128:1523-1527.
15. Sharei V, Höhn F, Köhler T, et al. Course of intraocular pressure after intravitreal injection of 0.05 mL ranibizumab (Lucentis). Eur J Ophthalmol. 2010;20:174-179.
16. Tseng JJ, Vance SK, Della Torre KE, et al. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. J Glaucoma. 2012;21:241-247.
17. Good TJ, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol. 2011;95:1111-1114.
18. Serbecic N, Beutelspacher SC, Aboul-Enein FC, et al. Reproducibility of high-resolution optical coherence tomography measurements of the nerve fibre layer with the new Heidelberg Spectralis optical coherence tomography. Br J Ophthalmol. 2011;95:804-810.